New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
09:45 EDTENTA, ENTA, ENTAEnanta Pharmaceuticals has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov will host a conference call with CEO Jay Luly on February 28 at 10 am.
News For ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
18:49 EDTENTAEnanta will not exercise co-development option for ABT-493
Enanta Pharmaceuticals (ENTA) announced that it has decided not to exercise its co-development option for ABT-493, Enanta’s next-generation protease inhibitor for hepatitis C virus, or HCV, being developed in Enanta’s collaboration with AbbVie (ABBV). Per the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well as royalties on net sales allocable to ABT-493 from worldwide sales of any ABT-493-containing regimens. Enanta also announced that it has reached agreement with AbbVie regarding the net sales allocations for royalty calculations for ABT-450-containing regimens, as well as any regimens containing ABT-493. ABT-450 is the first clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration, and ABT-493 is the second.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use